Catalio Capital Management, LP, a NYC-based life sciences investment firm, closed its second venture fund, Catalio Nexus II, at $100m.
The fund received support from private equity and hedge fund investors, as well as institutional family offices and foundations. In addition to closing the vehicle, Catalio announced the opening of a flagship office in Manhattan to facilitate the firm’s rapid growth.
Led by co-founders and Managing Partners George Petrocheilos and Dr. Jacob Vogelstein, Catalio Capital Management focuses on investing in breakthrough biomedical technology companies developing the next generation of drugs, devices, diagnostics and data-driven insights. Its General Partnership includes 25 world-renowned scientists with extensive academic bona fides who have also started several successful companies based on their research.
Other Key members of the leadership team include its Chairman, Edward J. Mathias, who was instrumental in the founding of The Carlyle Group (NASDAQ: CG) and a member of its Board of Directors from the firm’s IPO until his retirement in 2019; as well as General Partners and Investment Committee Members Tom V. Brooks and Dr. Kenan Turnacioglu.
Dr. Freda Lewis Hall, the recently retired Chief Medical Officer & Executive Vice President of Pfizer (NYSE: PFE), joined Catalio earlier this month as the newest Venture Partner.
Catalio invests in companies at all stages of development, from inception to IPO. The firm has raised nearly $150 million since inception and invested in 20 innovative, high-growth life sciences companies founded or referred by an elite group of world-renowned serial scientist-entrepreneurs who serve as Venture Partners. Its investments this year include liquid biopsy companies Thrive Earlier Detection and Freenome, the drug discovery platform company Recursion Pharma, and mental health start-up COMPASS Pathways (NASDAQ: CMPS), which went public in September.
The firm has offices in New York, Baltimore, and Washington, DC.